MXPA04005831A - Uso de una composicion farmaceutica que contiene factor de crecimiento epidermico (egf) para prevencion de amputacion del pie diabetico. - Google Patents
Uso de una composicion farmaceutica que contiene factor de crecimiento epidermico (egf) para prevencion de amputacion del pie diabetico.Info
- Publication number
- MXPA04005831A MXPA04005831A MXPA04005831A MXPA04005831A MXPA04005831A MX PA04005831 A MXPA04005831 A MX PA04005831A MX PA04005831 A MXPA04005831 A MX PA04005831A MX PA04005831 A MXPA04005831 A MX PA04005831A MX PA04005831 A MXPA04005831 A MX PA04005831A
- Authority
- MX
- Mexico
- Prior art keywords
- lesions
- composition
- egf
- growth factor
- epidermal growth
- Prior art date
Links
- 208000008960 Diabetic foot Diseases 0.000 title abstract 2
- 238000002266 amputation Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 3
- 208000025865 Ulcer Diseases 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 230000007654 ischemic lesion Effects 0.000 abstract 2
- 230000003902 lesion Effects 0.000 abstract 2
- 238000001356 surgical procedure Methods 0.000 abstract 2
- 231100000397 ulcer Toxicity 0.000 abstract 2
- 230000001154 acute effect Effects 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000008595 infiltration Effects 0.000 abstract 1
- 238000001764 infiltration Methods 0.000 abstract 1
- 208000028867 ischemia Diseases 0.000 abstract 1
- 230000001926 lymphatic effect Effects 0.000 abstract 1
- 238000004321 preservation Methods 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
- 238000002278 reconstructive surgery Methods 0.000 abstract 1
- 230000010410 reperfusion Effects 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
- 230000002792 vascular Effects 0.000 abstract 1
- 230000035899 viability Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1808—Epidermal growth factor [EGF] urogastrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Uso del factor de crecimiento Epidermico (EGF) en una composicion farmaceutica preferiblemente inyectable, para ser administrada mediante infiltracion dentro y alrededor de lesiones cutaneas isquemicas cronicas, para prevenir la amputacion del pie diabetico. Puede administrarse sobre superficies quirurgicas de reciente creacion y danadas por el efecto de referfusion aguda con sangre oxigenada luego de prolongada isquemia, previniendo reintervenciones quirurgicas y favoreciendo la preservacion de la extremidad. Esta composicion logra mejorar el microambiente celular incrementando la viabilidad, capacidad defensiva y reparativa de los tejidos, y la cicatrizacion de lesiones cutaneas isquemicas, estimulando la proliferacion celular. Es aplicable en medicina humana, veterinaria y experimental, especificamente en angiologia y cirugia vascular, dermatologia, caumatologia-cirugia, reconstructiva, y geriatria. Se aplica en ulceras recalcitrantes asociadas a lesiones en la macro y/o microvasculatura, a sujetos con insuficiente retorno venoso y/o linfatico y en ulceras u otras lesiones rebeldes a la cicatrizacion y/o curacion.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU20010308A CU23043A1 (es) | 2001-12-20 | 2001-12-20 | Composicion farmaceutica que contiene factor de crecimiento epidrmico (egf) para la prevencion de la amputacion de pie diabetico. |
| PCT/CU2002/000011 WO2003053458A1 (es) | 2001-12-20 | 2002-12-04 | Uso de una composición farmacéutica que contiene factor de crecimiento epidérmico (egf) para la prevención de la amputación del pie diabético |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA04005831A true MXPA04005831A (es) | 2004-09-13 |
Family
ID=40239814
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA04005831A MXPA04005831A (es) | 2001-12-20 | 2002-12-04 | Uso de una composicion farmaceutica que contiene factor de crecimiento epidermico (egf) para prevencion de amputacion del pie diabetico. |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US7465704B2 (es) |
| EP (1) | EP1466617B1 (es) |
| JP (1) | JP4808378B2 (es) |
| KR (1) | KR100795654B1 (es) |
| CN (1) | CN1306954C (es) |
| AR (1) | AR037824A1 (es) |
| AT (1) | ATE422897T1 (es) |
| AU (1) | AU2002361923B2 (es) |
| BR (1) | BRPI0215214B8 (es) |
| CA (1) | CA2470971C (es) |
| CU (1) | CU23043A1 (es) |
| DE (1) | DE60231248D1 (es) |
| DK (1) | DK1466617T3 (es) |
| ES (1) | ES2322568T3 (es) |
| MX (1) | MXPA04005831A (es) |
| MY (1) | MY139214A (es) |
| PT (1) | PT1466617E (es) |
| RU (1) | RU2289424C2 (es) |
| SI (1) | SI1466617T1 (es) |
| UA (1) | UA80813C2 (es) |
| WO (1) | WO2003053458A1 (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU23043A1 (es) | 2001-12-20 | 2005-05-20 | Ct Ingenieria Genetica Biotech | Composicion farmaceutica que contiene factor de crecimiento epidrmico (egf) para la prevencion de la amputacion de pie diabetico. |
| CU23529A1 (es) * | 2005-03-02 | 2010-06-17 | Ct Ingenieria Genetica Biotech | Combinación de egf/ghrp-6 para la neuroregeneración del sistema nervioso central posterior al dano autoinmune |
| CU23411B6 (es) * | 2005-12-29 | 2009-09-08 | Ct Ingenieria Genetica Biotech | Uso tópico del factor de crecimiento epidérmico en liposomas para prevenir la amputación del pie diabético |
| CU23388B6 (es) * | 2006-01-31 | 2009-07-16 | Ct Ingenieria Genetica Biotech | Composición farmacéutica de microesferas para prevenir la amputación del pie diabético |
| CU23558A1 (es) | 2006-02-28 | 2010-07-20 | Ct Ingenieria Genetica Biotech | Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento |
| CU23526B6 (es) | 2006-10-03 | 2010-05-19 | Ct Ingenieria Genetica Biotech | Método para la restauración morfofuncional de nervios periféricos en la neuropatía diabética |
| US8211947B2 (en) * | 2008-01-28 | 2012-07-03 | Guillermo Selman-Housein Sosa | Composition and method for treating and preventing musculoskeletal and connective tissue disorders |
| ES2340902B1 (es) | 2008-07-01 | 2011-05-03 | Laboratorios Farmaceuticos Rovi, S.A. | Composicion farmaceutica con glicosaminoglicanos y su uso en tratamiento de ulceras cronicas. |
| CN101496486B (zh) * | 2009-03-13 | 2011-02-16 | 新疆巴音郭楞蒙古自治州农业科学研究所 | 一种蘑菇栽培方法 |
| ES2357601B1 (es) | 2011-01-26 | 2012-03-21 | Laboratorios Farmacéuticos Rovi, S.A. | Procedimiento de preparación de derivados de glicosaminoglicanos donadores de óxido n�?trico y su uso en tratamiento de úlceras crónicas. |
| ES2468740B1 (es) | 2012-11-13 | 2015-04-01 | Consejo Superior De Investigaciones Científicas (Csic) | Apósito para cicatrización de heridas comprometidas |
| US9387151B2 (en) | 2013-08-20 | 2016-07-12 | Anutra Medical, Inc. | Syringe fill system and method |
| USD774182S1 (en) | 2014-06-06 | 2016-12-13 | Anutra Medical, Inc. | Anesthetic delivery device |
| USD763433S1 (en) | 2014-06-06 | 2016-08-09 | Anutra Medical, Inc. | Delivery system cassette |
| USD750768S1 (en) | 2014-06-06 | 2016-03-01 | Anutra Medical, Inc. | Fluid administration syringe |
| CN104173366A (zh) * | 2014-09-14 | 2014-12-03 | 陈钏黄 | 一种三磷酸腺苷二钠在制备治疗糖尿病足药物中的应用 |
| MX389934B (es) * | 2016-12-09 | 2025-03-20 | Desarrolladora Y Com De Tecnologias Biomedicas Decotecbio S A De C V | Composición coadyuvante de un factor de crecimiento y un neuropéptido para acelerar la cicatrización de heridas y la repitelización de órganos. |
| WO2019006127A1 (en) * | 2017-06-28 | 2019-01-03 | Rutgers, The State University Of New Jersey | ORGANOIDS DERIVED FROM A SINGLE RENAL CELL |
| US20210155896A1 (en) * | 2017-06-28 | 2021-05-27 | Rutgers, The State University Of New Jersey | Single brain cell-derived organoids |
| CU20190022A7 (es) * | 2019-03-18 | 2020-10-20 | Centro De Ingenieria Genetica Y Biotecnologia Biocubafarma | Composición farmacéutica para el tratamiento de la úlcera del pie diabético |
| US20250290138A1 (en) | 2020-09-21 | 2025-09-18 | Korea University Research And Business Foundation | Method for prediction of recurrence or prognosis of diabetic foot ulcer by using specific methylation of gene |
| KR102581240B1 (ko) | 2020-09-21 | 2023-09-22 | 고려대학교 산학협력단 | 유전자의 특이적 메틸화를 이용하여 당뇨족부궤양 재발 또는 예후를 예측하는 방법 |
| KR102838081B1 (ko) | 2022-04-12 | 2025-07-24 | 고려대학교 산학협력단 | 마이크로바이옴을 이용하여 당뇨족부궤양 예후를 예측하는 방법 |
| WO2025242247A1 (es) | 2024-05-21 | 2025-11-27 | Centro De Ingeniería Genética Y Biotecnología | Uso del péptido ghrp-6 para el tratamiento de la senescencia y la cicatrización de heridas crónicas complejas refractarias |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1417776A (en) * | 1973-03-28 | 1975-12-17 | Ici Ltd | Pharmaceutical compositions |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| NZ226171A (en) * | 1987-09-18 | 1990-06-26 | Ethicon Inc | Gel formulation containing polypeptide growth factor |
| JP2670680B2 (ja) | 1988-02-24 | 1997-10-29 | 株式会社ビーエムジー | 生理活性物質含有ポリ乳酸系微小球およびその製造法 |
| US5034375A (en) * | 1988-08-10 | 1991-07-23 | Institute Of Molecular Biology, Inc. | Process of wound healing using PDGF and EGF |
| US4944948A (en) | 1989-02-24 | 1990-07-31 | Liposome Technology, Inc. | EGF/Liposome gel composition and method |
| KR920700691A (ko) | 1989-04-04 | 1992-08-10 | 존.에프.맥인티리 | 상처부위, 절개부위, 찰과상 부위에 치료제의 투여에 대한 리포좀(liposomes)의 용도 |
| US5130298A (en) * | 1989-05-16 | 1992-07-14 | Ethicon, Inc. | Stabilized compositions containing epidermal growth factor |
| WO1991001719A1 (en) | 1989-08-01 | 1991-02-21 | The University Of Michigan | Topical delivery of peptides/proteins entrapped in dehydration/rehydration liposomes |
| AU629316B2 (en) | 1990-04-11 | 1992-10-01 | Flora Inc. | Periodontal disease treatment system |
| DK0564502T3 (da) * | 1990-11-27 | 2002-05-13 | Univ Loyola Chicago | Vævsforseglingsmiddel og vækstfaktorholdige præparater, der fremmer accelereret sårheling |
| CN1160582A (zh) * | 1996-12-27 | 1997-10-01 | 暨南大学生物工程研究所 | 含有细胞生长因子的皮肤外用组合物 |
| RU2144831C1 (ru) * | 1998-11-02 | 2000-01-27 | Дальневосточный государственный медицинский университет | Способ лечения синдрома диабетической стопы |
| AU2001279073B2 (en) * | 2000-07-28 | 2006-08-24 | Christopher J. Murphy | Transplant media |
| CU23043A1 (es) | 2001-12-20 | 2005-05-20 | Ct Ingenieria Genetica Biotech | Composicion farmaceutica que contiene factor de crecimiento epidrmico (egf) para la prevencion de la amputacion de pie diabetico. |
| CN100571773C (zh) | 2002-03-12 | 2009-12-23 | 生物键有限公司 | 采用表皮生长因子治疗皮肤伤口的方法和组合物 |
| CN1720989A (zh) | 2004-07-15 | 2006-01-18 | 深圳市清华源兴生物医药科技有限公司 | 一种表皮生长因子缓释微球及其制备方法与应用 |
-
2001
- 2001-12-20 CU CU20010308A patent/CU23043A1/es unknown
-
2002
- 2002-12-04 PT PT27964915T patent/PT1466617E/pt unknown
- 2002-12-04 BR BRPI0215214A patent/BRPI0215214B8/pt not_active IP Right Cessation
- 2002-12-04 SI SI200230818T patent/SI1466617T1/sl unknown
- 2002-12-04 AT AT02796491T patent/ATE422897T1/de active
- 2002-12-04 KR KR1020047009772A patent/KR100795654B1/ko not_active Expired - Lifetime
- 2002-12-04 CA CA2470971A patent/CA2470971C/en not_active Expired - Lifetime
- 2002-12-04 WO PCT/CU2002/000011 patent/WO2003053458A1/es not_active Ceased
- 2002-12-04 AU AU2002361923A patent/AU2002361923B2/en not_active Expired
- 2002-12-04 CN CNB02828268XA patent/CN1306954C/zh not_active Expired - Lifetime
- 2002-12-04 EP EP02796491A patent/EP1466617B1/en not_active Expired - Lifetime
- 2002-12-04 DE DE60231248T patent/DE60231248D1/de not_active Expired - Lifetime
- 2002-12-04 US US10/499,457 patent/US7465704B2/en not_active Expired - Lifetime
- 2002-12-04 ES ES02796491T patent/ES2322568T3/es not_active Expired - Lifetime
- 2002-12-04 MX MXPA04005831A patent/MXPA04005831A/es active IP Right Grant
- 2002-12-04 DK DK02796491T patent/DK1466617T3/da active
- 2002-12-04 UA UA20040705897A patent/UA80813C2/xx unknown
- 2002-12-04 RU RU2004122091/15A patent/RU2289424C2/ru active
- 2002-12-04 JP JP2003554215A patent/JP4808378B2/ja not_active Expired - Fee Related
- 2002-12-13 AR ARP020104843A patent/AR037824A1/es active IP Right Grant
- 2002-12-18 MY MYPI20024760A patent/MY139214A/en unknown
-
2008
- 2008-08-22 US US12/197,001 patent/US7799760B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| SI1466617T1 (sl) | 2009-08-31 |
| EP1466617A1 (en) | 2004-10-13 |
| AR037824A1 (es) | 2004-12-09 |
| JP2005516024A (ja) | 2005-06-02 |
| CN1306954C (zh) | 2007-03-28 |
| US20080312139A1 (en) | 2008-12-18 |
| US7465704B2 (en) | 2008-12-16 |
| BRPI0215214B8 (pt) | 2021-05-25 |
| HK1077740A1 (en) | 2006-02-24 |
| US20050107294A1 (en) | 2005-05-19 |
| ES2322568T3 (es) | 2009-06-23 |
| KR20040094669A (ko) | 2004-11-10 |
| UA80813C2 (en) | 2007-11-12 |
| PT1466617E (pt) | 2009-05-20 |
| RU2004122091A (ru) | 2005-04-10 |
| BRPI0215214B1 (pt) | 2017-05-30 |
| CA2470971A1 (en) | 2003-07-03 |
| CN1620308A (zh) | 2005-05-25 |
| AU2002361923B2 (en) | 2006-02-02 |
| JP4808378B2 (ja) | 2011-11-02 |
| KR100795654B1 (ko) | 2008-01-21 |
| DK1466617T3 (da) | 2009-06-15 |
| US7799760B2 (en) | 2010-09-21 |
| ATE422897T1 (de) | 2009-03-15 |
| MY139214A (en) | 2009-08-28 |
| RU2289424C2 (ru) | 2006-12-20 |
| BR0215214A (pt) | 2004-12-07 |
| CA2470971C (en) | 2011-02-01 |
| EP1466617B1 (en) | 2009-02-18 |
| AU2002361923A1 (en) | 2003-07-09 |
| DE60231248D1 (de) | 2009-04-02 |
| CU23043A1 (es) | 2005-05-20 |
| WO2003053458A1 (es) | 2003-07-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA04005831A (es) | Uso de una composicion farmaceutica que contiene factor de crecimiento epidermico (egf) para prevencion de amputacion del pie diabetico. | |
| Daunton et al. | A history of materials and practices for wound management | |
| Collins et al. | Diagnosis and treatment of venous ulcers | |
| Lancerotto et al. | Mechanisms of action of microdeformational wound therapy | |
| Merz et al. | Fungating wounds–multidimensional challenge in palliative care | |
| CN103933603B (zh) | 一种壳聚糖促人表皮生长生物医用胶及其制备方法 | |
| CN106728727A (zh) | 一种治疗疮疡的药膏及其制备方法 | |
| Niculescu et al. | Therapeutic management of malignant wounds: an update | |
| CN101264196B (zh) | 用于治疗外科伤口的外用药物组合物及其膏剂的制备方法 | |
| US20160346335A1 (en) | Honey-based dressing for the treatment of wounds and burns | |
| CN102133340A (zh) | 一种外用中药创灼贴剂及其制备方法 | |
| Furtado et al. | Wound healing concepts: contemporary practices and future perspectives | |
| CN103893816A (zh) | 含植物成分的细菌纤维素复合羊膜细胞外基质敷料制备方法 | |
| Njokweni | Adjunctive topical oxygen therapy in the management of complex diabetes-related wounds: A South African case study series | |
| Sarheed et al. | Honey products and their potential in wound healing | |
| Yildiz et al. | Recipient site necrosis after tumescent infiltration with adrenaline in hair transplantation | |
| RU2329822C1 (ru) | Антисептическое, противовоспалительное, болеутоляющее средство | |
| Cho et al. | Successful combined treatment with total parenteral nutrition fluid extravasation injuries in preterm infants | |
| Atiyeh et al. | The efficacy of moisture retentive ointment in the mangement of cutaneous wounds and ulcers: A multicenter clinical trial | |
| Iqbal et al. | Pressure Ulcers in Older Adults: Management | |
| CN108686078B (zh) | 一种治疗压疮的中药散剂 | |
| Mabrouk et al. | Use of Lyophilized Growth Factors Foam in Chronic Ulcers | |
| Foutsizoglou | A practical guide to the most commonly used dressings in wound care | |
| Wongprachum | Innovative topical haemoglobin spray helps drive the MOIST concept in saving patients’ limbs | |
| Oe | Supplementary Table on" Managements for Controlling Inflammation/Infection in Diabetic Foot Ulcers: A Scoping Review" |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |